Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Short term Debt (2016 - 2017)

Bone Biologics has reported Short term Debt over the past 3 years, most recently at $12.9 million for Q3 2017.

  • Quarterly Short term Debt rose 43.33% to $12.9 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Sep 2017, up 43.33% year-over-year, with the annual reading at $1.2 million for FY2016, 40.0% down from the prior year.
  • Short term Debt was $12.9 million for Q3 2017 at Bone Biologics, up from $12.2 million in the prior quarter.
  • Over five years, Short term Debt peaked at $12.9 million in Q3 2017 and troughed at $1.2 million in Q4 2016.
  • The 3-year median for Short term Debt is $9.0 million (2016), against an average of $8.4 million.
  • Year-over-year, Short term Debt tumbled 40.0% in 2016 and then skyrocketed 43.33% in 2017.
  • A 3-year view of Short term Debt shows it stood at $2.0 million in 2015, then tumbled by 40.0% to $1.2 million in 2016, then soared by 975.0% to $12.9 million in 2017.
  • Per Business Quant, the three most recent readings for BBLG's Short term Debt are $12.9 million (Q3 2017), $12.2 million (Q2 2017), and $12.2 million (Q1 2017).